Immix Biopharma (NASDAQ: IMMX)

Last close As at 23/01/2026

USD5.38

0.13 (2.48%)

Market capitalisation

USD279m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Update

Immix Biopharma — NXC-201’s path to BLA submission

Healthcare | Update

Immix Biopharma — Primed to pick up the pace in ALA

Healthcare | Comment

Immix (NASDAQ: IMMX) to present NEXICART-2 update at ASH 2025

Scientist using protective robber gloves for handling substances and experiments

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Thematics